Results 211 to 220 of about 199,284 (357)

Succinate Promotes M1 Polarization of Intestinal Macrophages in Mice With Necrotizing Enterocolitis Through the PI3K/AKT Pathway

open access: yesPediatric Discovery, EarlyView.
Succinate promotes macrophage to the M1 phenotype in the mouse mononuclear macrophage leukemia cells (Raw264.7 cells) and neonatal mice with NEC. Succinate activates the phosphatidylinositol 3‐kinase/protein kinase B (PI3K/AKT) pathway via succinate recepter 1 (SUCNR1), promoting M1 polarization of NEC intestinal macrophages.
Sha Liu   +6 more
wiley   +1 more source

Analysis of C4 Concentrations to Predict Impact of Patient‐Reported Diarrhea Associated With the Ileal Bile Acid Transporter Inhibitor Linerixibat

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 596-605, March 2025.
ABSTRACT Linerixibat, an ileal bile acid transporter (IBAT) inhibitor, is being evaluated for the treatment of pruritus in primary biliary cholangitis (PBC). Diarrhea is commonly reported with this drug class as IBAT inhibition redirects bile acids (BA) to the colon.
Fernando Carreño   +4 more
wiley   +1 more source

Nanomedicine for Oral Delivery: Strategies to Overcome the Biological Barriers

open access: yesSmall Methods, EarlyView.
Oral delivery is a preferred administration route for many clinical applications, valued for its strong patient compliance. In this review, how nanoparticles are engineered and deployed to overcome the gastrointestinal barriers that impede clinical translation of oral delivery formulations is examined.
Luke J. Kubiatowicz   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy